Brokerages forecast that Chemed Co. (NYSE:CHE) will report $2.28 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Chemed’s earnings. The lowest EPS estimate is $2.27 and the highest is $2.28. Chemed reported earnings of $2.10 per share during the same quarter last year, which would suggest a positive year over year growth rate of 8.6%. The firm is expected to issue its next quarterly earnings report on Wednesday, February 21st.

According to Zacks, analysts expect that Chemed will report full-year earnings of $8.39 per share for the current financial year, with EPS estimates ranging from $8.38 to $8.39. For the next fiscal year, analysts anticipate that the company will post earnings of $8.94 per share, with EPS estimates ranging from $8.76 to $9.12. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Chemed.

Chemed (NYSE:CHE) last released its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.15. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The firm had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. During the same quarter in the previous year, the company earned $1.73 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year.

A number of research firms have issued reports on CHE. ValuEngine cut shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 price objective on the stock in a research report on Thursday, November 2nd. Royal Bank of Canada boosted their price objective on shares of Chemed to $232.00 and gave the company a “sector perform” rating in a research report on Tuesday, October 31st. TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Finally, Oppenheimer boosted their price objective on shares of Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $236.00.

In related news, insider David Patrick Williams sold 11,000 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the transaction, the insider now owns 74,857 shares in the company, valued at $18,061,496.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick P. Grace sold 500 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $201.48, for a total transaction of $100,740.00. Following the transaction, the director now owns 4,515 shares in the company, valued at approximately $909,682.20. The disclosure for this sale can be found here. Insiders have sold 46,179 shares of company stock worth $10,729,699 in the last quarter. 4.90% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in Chemed by 111.5% during the third quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock worth $36,125,000 after acquiring an additional 96,237 shares in the last quarter. Voya Investment Management LLC boosted its stake in Chemed by 39.7% during the second quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock worth $43,926,000 after acquiring an additional 61,056 shares in the last quarter. Old Mutual Global Investors UK Ltd. boosted its stake in Chemed by 173.5% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 95,212 shares of the company’s stock worth $19,237,000 after acquiring an additional 60,399 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Chemed by 248.5% during the second quarter. Renaissance Technologies LLC now owns 70,400 shares of the company’s stock worth $14,399,000 after acquiring an additional 50,200 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Chemed by 1.9% during the second quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock worth $374,435,000 after acquiring an additional 34,938 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Chemed (CHE) traded up $0.45 during mid-day trading on Wednesday, hitting $235.21. 125,100 shares of the company’s stock were exchanged, compared to its average volume of 94,732. Chemed has a 12-month low of $152.01 and a 12-month high of $251.00. The stock has a market capitalization of $3,748.18, a PE ratio of 28.91, a price-to-earnings-growth ratio of 4.96 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48.

The business also recently declared a quarterly dividend, which was paid on Monday, December 4th. Investors of record on Monday, November 13th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend was Friday, November 10th. Chemed’s dividend payout ratio is currently 24.89%.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Chemed Co. (CHE) to Announce $2.28 Earnings Per Share” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/13/zacks-brokerages-anticipate-chemed-co-che-to-announce-2-28-earnings-per-share.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Get a free copy of the Zacks research report on Chemed (CHE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.